There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tyme Technologies Inc (NASDAQ: TYME) and BioMarin (NASDAQ: BMRN) with bullish sentiments.
Tyme Technologies Inc (NASDAQ: TYME)
In a report released today, Arlinda Lee from Canaccord Genuity maintained a Buy rating on Tyme Technologies Inc (NASDAQ: TYME), with a price target of $10. The company’s shares opened today at $3.55.
Lee observed:
“We continue to view SM-88’s ability to generate responses across ~15 solid and liquid tumor types and with durable effect in advanced cancer patients progressing on available therapies as intriguing and reiterate our BUY rating.”
According to TipRanks.com, Lee is a 4-star analyst with an average return of 7.0% and a 47.4% success rate. Lee covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Aquinox Pharmaceuticals, and Zynerba Pharmaceuticals.
Tyme Technologies Inc has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.
See today’s analyst top recommended stocks >>
BioMarin (NASDAQ: BMRN)
Wedbush analyst Liana Moussatos reiterated a Buy rating on BioMarin (NASDAQ: BMRN) today and set a price target of $115. The company’s shares opened today at $90.43.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.9% and a 45.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
BioMarin has an analyst consensus of Strong Buy, with a price target consensus of $118.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.